Document is current
Any future updates will be listed below
-
Authors
Malandris, Konstantinos
Charalampidis, Konstantinos
Loomba, Rohit
Sinakos, Emmanouil
-
Funding
Funding for this research was provided by:
Aristotle University of Thessaloniki
- License Information
-
More Information
Article History
Received: 29 January 2026
Accepted: 2 March 2026
First Online: 14 March 2026
Declarations
:
: KM and KC declare no conflicts of interest. ES participates in clinical trials for NovoNordisk, GlaxoSmithKline and Boehringer Ingelheim; Stockholder in Akero Therapeutics and 89bio. RL serves as a consultant to Aardvark Therapeutics, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Cascade Pharmaceuticals, Eli Lilly, Gilead, Glympse bio, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89 bio, Takeda, Terns Pharmaceuticals and Viking Therapeutics. RL has stock options in Sagimet biosciences. In addition, his institution received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Pfizer, Sonic Incytes and Terns Pharmaceuticals.
: KM and KC declare no conflicts of interest. ES participates in clinical trials for NovoNordisk, GlaxoSmithKline and Boehringer Ingelheim; Stockholder in Akero Therapeutics and 89bio. RL serves as a consultant to Aardvark Therapeutics, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Cascade Pharmaceuticals, Eli Lilly, Gilead, Glympse bio, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89 bio, Takeda, Terns Pharmaceuticals and Viking Therapeutics. RL has stock options in Sagimet biosciences. In addition, his institution received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Pfizer, Sonic Incytes and Terns Pharmaceuticals. RL receives funding support from NCATS (5UL1TR001442), NIDDK (U01DK061734, U01DK130190, R01DK121378, P30DK120515), NHLBI (P01HL147835), and John C Martin Foundation (RP124).
